Literature DB >> 21315423

Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas.

Elias Drakos1, Vasiliki Leventaki, Vasileios Atsaves, Ellen J Schlette, Pei Lin, Francisco Vega, Roberto N Miranda, Francois-Xavier Claret, L Jeffrey Medeiros, George Z Rassidakis.   

Abstract

Fas-associated death domain protein is a key component of the extrinsic apoptotic pathway. In addition, in animal models, Fas-associated death domain protein phosphorylation at serine 194 has been shown to affect cell proliferation, especially in T lymphocytes. The importance of Fas-associated death domain protein phosphorylation at serine 194 for the proliferation of B lymphocytes, however, is uncertain. Here we show in reactive lymph nodes that serine 194 phosphorylated Fas-associated death domain protein is expressed predominantly in the dark (proliferative) zone of germinal centers. In B-cell non-Hodgkin lymphoma cell lines, serine 194 phosphorylated Fas-associated death domain protein levels are substantially higher in highly proliferating cells and lower in serum-starved cells. We also used immunohistochemical analysis to assess Fas-associated death domain protein phosphorylation at serine 194 expression in 122 B-cell non-Hodgkin-type lymphomas. The mean percentage of serine 194 phosphorylated Fas-associated death domain protein positive tumor cells was 81% in Burkitt lymphoma, 41% in diffuse large B-cell lymphoma, 18% in follicular lymphoma, 18% in plasma cell myeloma, 12% in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue, 11% in mantle cell lymphoma, and 2% in chronic lymphocytic leukemia/small lymphocytic lymphoma (P < .0001, Kruskal-Wallis test). Furthermore, in chronic lymphocytic leukemia/small lymphocytic lymphoma, serine 194 phosphorylated Fas-associated death domain protein was detected predominantly in proliferation centers. In the entire study group, the percentage of cells positive for serine 194 phosphorylated Fas-associated death domain protein correlated significantly with the proliferation index Ki-67 (Spearman R = 0.9, P < .0001). These data provide evidence that serine 194 phosphorylated Fas-associated death domain protein is involved in the proliferation of normal and neoplastic B cells and has features of a novel proliferation marker.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21315423      PMCID: PMC4089890          DOI: 10.1016/j.humpath.2010.11.002

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  34 in total

Review 1.  FADD and its phosphorylation.

Authors:  Jing Zhang; Dapeng Zhang; Zichun Hua
Journal:  IUBMB Life       Date:  2004-07       Impact factor: 3.885

2.  FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.

Authors:  A M Chinnaiyan; K O'Rourke; M Tewari; V M Dixit
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

3.  Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression.

Authors:  Keiji Shimada; Syuichi Matsuyoshi; Mitsutoshi Nakamura; Eiwa Ishida; Noboru Konishi
Journal:  J Pathol       Date:  2005-08       Impact factor: 7.996

4.  Absence or low expression of fas-associated protein with death domain in acute myeloid leukemia cells predicts resistance to chemotherapy and poor outcome.

Authors:  Léa Tourneur; Stéphanie Delluc; Vincent Lévy; Françoise Valensi; Isabelle Radford-Weiss; Ollivier Legrand; Jacques Vargaftig; Charlotte Boix; Elizabeth A Macintyre; Bruno Varet; Gilles Chiocchia; Agnès Buzyn
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

Review 5.  Nonapoptotic functions of FADD-binding death receptors and their signaling molecules.

Authors:  Sun-Mi Park; Robert Schickel; Marcus E Peter
Journal:  Curr Opin Cell Biol       Date:  2005-10-13       Impact factor: 8.382

6.  Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1.

Authors:  J Zhang; D Cado; A Chen; N H Kabra; A Winoto
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

7.  Phosphorylated FADD induces NF-kappaB, perturbs cell cycle, and is associated with poor outcome in lung adenocarcinomas.

Authors:  Guoan Chen; Mahaveer S Bhojani; Andrew C Heaford; Daniel C Chang; Bharathi Laxman; Dafydd G Thomas; Laura B Griffin; James Yu; Julia M Coppola; Thomas J Giordano; Lin Lin; David Adams; Mark B Orringer; Brian D Ross; David G Beer; Alnawaz Rehemtulla
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-18       Impact factor: 11.205

8.  Phosphorylation of FADD at serine 194 by CKIalpha regulates its nonapoptotic activities.

Authors:  Elizabeth C Alappat; Christine Feig; Benjamin Boyerinas; Jörg Volkland; Martin Samuels; Andrea E Murmann; Andrew Thorburn; Vincent J Kidd; Clive A Slaughter; Stephanie L Osborn; Astar Winoto; Wei-Jen Tang; Marcus E Peter
Journal:  Mol Cell       Date:  2005-08-05       Impact factor: 17.970

9.  Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma.

Authors:  George Z Rassidakis; Marianna Feretzaki; Coralyn Atwell; Ioannis Grammatikakis; Quan Lin; Raymond Lai; Francois-Xavier Claret; L Jeffrey Medeiros; Hesham M Amin
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

10.  The death domain of FADD is essential for embryogenesis, lymphocyte development, and proliferation.

Authors:  Hongxia Z Imtiyaz; Xiaohui Zhou; Haibing Zhang; Dehua Chen; Taishan Hu; Jianke Zhang
Journal:  J Biol Chem       Date:  2009-02-09       Impact factor: 5.157

View more
  8 in total

1.  Phosphorylation of FADD by the kinase CK1α promotes KRASG12D-induced lung cancer.

Authors:  Brittany M Bowman; Katrina A Sebolt; Benjamin A Hoff; Jennifer L Boes; Danette L Daniels; Kevin A Heist; Craig J Galbán; Rajiv M Patel; Jianke Zhang; David G Beer; Brian D Ross; Alnawaz Rehemtulla; Stefanie Galbán
Journal:  Sci Signal       Date:  2015-01-27       Impact factor: 8.192

2.  The Classical Apoptotic Adaptor FADD Regulates Glycolytic Capacity in Acute Lymphoblastic Leukemia.

Authors:  Wenzhao Zhou; Yueyang Lai; Jianhui Zhu; Xuebo Xu; Wenliang Yu; Zengzheng Du; Leyang Wu; Xuerui Zhang; Zichun Hua
Journal:  Int J Biol Sci       Date:  2022-05-01       Impact factor: 10.750

3.  Pin1-FADD interactions regulate Fas-mediated apoptosis in activated eosinophils.

Authors:  Jiyoung Oh; James S Malter
Journal:  J Immunol       Date:  2013-04-19       Impact factor: 5.422

4.  Increased Expression of Phosphorylated FADD in Anaplastic Large Cell and Other T-Cell Lymphomas.

Authors:  Suketu Patel; Derek Murphy; Eugenia Haralambieva; Zainalabideen A Abdulla; Kah Keng Wong; Hong Chen; Edith Gould; Giovanna Roncador; Chris Hatton; Amanda P Anderson; Alison H Banham; Karen Pulford
Journal:  Biomark Insights       Date:  2014-09-03

5.  Deregulated FADD expression and phosphorylation in T-cell lymphoblastic lymphoma.

Authors:  José L Marín-Rubio; María C de Arriba; María A Cobos-Fernández; Laura González-Sánchez; Inmaculada Ors; Isabel Sastre; José Fernández-Piqueras; María Villa-Morales
Journal:  Oncotarget       Date:  2016-09-20

6.  A long-term retrospective study on sporadic Burkitt lymphoma in chinese population.

Authors:  Xiaoyun Yang; Qianru Huang; An Li; Yuan Chen; Wei Xu; Jianyong Li; Yaping Wang; Yongjun Fang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

7.  Cholecystokinin octapeptide antagonizes apoptosis in human retinal pigment epithelial cells.

Authors:  Yuan Liu; Yueling Zhang; Zhaohui Gu; Lina Hao; Juan Du; Qian Yang; Suping Li; Liying Wang; Shilei Gong
Journal:  Neural Regen Res       Date:  2014-07-15       Impact factor: 5.135

Review 8.  FADD in Cancer: Mechanisms of Altered Expression and Function, and Clinical Implications.

Authors:  José L Marín-Rubio; Laura Vela-Martín; José Fernández-Piqueras; María Villa-Morales
Journal:  Cancers (Basel)       Date:  2019-09-29       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.